Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 21 entries
Sorted by: Best Match Show Resources per page
Germline whole exome sequencing and large-scale replication identifies .

Oncotarget

Dicks E, Song H, Ramus SJ, Oudenhove EV, Tyrer JP, Intermaggio MP, Kar S, Harrington P, Bowtell DD, Group AS, Cicek MS, Cunningham JM, Fridley BL, Alsop J, Jimenez-Linan M, Piskorz A, Goranova T, Kent E, Siddiqui N, Paul J, Crawford R, Poblete S, Lele S, Sucheston-Campbell L, Moysich KB, Sieh W, McGuire V, Lester J, Odunsi K, Whittemore AS, Bogdanova N, Dürst M, Hillemanns P, Karlan BY, Gentry-Maharaj A, Menon U, Tischkowitz M, Levine D, Brenton JD, Dörk T, Goode EL, Gayther SA, Pharoah DPP.
PMID: 28881617
Oncotarget. 2017 Mar 03;8(31):50930-50940. doi: 10.18632/oncotarget.15871. eCollection 2017 Aug 01.

We analyzed whole exome sequencing data in germline DNA from 412 high grade serous ovarian cancer (HGSOC) cases from The Cancer Genome Atlas Project and identified 5,517 genes harboring a predicted deleterious germline coding mutation in at least one...

Cite
Dicks E, Song H, Ramus SJ, et al. Germline whole exome sequencing and large-scale replication identifies . Oncotarget. 2017;8(31):50930-50940doi: 10.18632/oncotarget.15871.
Dicks, E., Song, H., Ramus, S. J., Oudenhove, E. V., Tyrer, J. P., Intermaggio, M. P., Kar, S., Harrington, P., Bowtell, D. D., Group, A. S., Cicek, M. S., Cunningham, J. M., Fridley, B. L., Alsop, J., Jimenez-Linan, M., Piskorz, A., Goranova, T., Kent, E., Siddiqui, N., Paul, J., Crawford, R., Poblete, S., Lele, S., Sucheston-Campbell, L., Moysich, K. B., Sieh, W., McGuire, V., Lester, J., Odunsi, K., Whittemore, A. S., Bogdanova, N., Dürst, M., Hillemanns, P., Karlan, B. Y., Gentry-Maharaj, A., Menon, U., Tischkowitz, M., Levine, D., Brenton, J. D., Dörk, T., Goode, E. L., Gayther, S. A., & Pharoah, D. P. P. (2017). Germline whole exome sequencing and large-scale replication identifies . Oncotarget, 8(31), 50930-50940. https://doi.org/10.18632/oncotarget.15871
Dicks, Ed, et al. "Germline whole exome sequencing and large-scale replication identifies ." Oncotarget vol. 8,31 (2017): 50930-50940. doi: https://doi.org/10.18632/oncotarget.15871
Dicks E, Song H, Ramus SJ, Oudenhove EV, Tyrer JP, Intermaggio MP, Kar S, Harrington P, Bowtell DD, Group AS, Cicek MS, Cunningham JM, Fridley BL, Alsop J, Jimenez-Linan M, Piskorz A, Goranova T, Kent E, Siddiqui N, Paul J, Crawford R, Poblete S, Lele S, Sucheston-Campbell L, Moysich KB, Sieh W, McGuire V, Lester J, Odunsi K, Whittemore AS, Bogdanova N, Dürst M, Hillemanns P, Karlan BY, Gentry-Maharaj A, Menon U, Tischkowitz M, Levine D, Brenton JD, Dörk T, Goode EL, Gayther SA, Pharoah DPP. Germline whole exome sequencing and large-scale replication identifies . Oncotarget. 2017 Mar 03;8(31):50930-50940. doi: 10.18632/oncotarget.15871. eCollection 2017 Aug 01. PMID: 28881617; PMCID: PMC5584218.
Copy Download .nbib Format: NLM
Inferring active and prognostic ligand-receptor pairs with interactions in survival regression models.

Cancer informatics

Ruggeri C, Eng KH.
PMID: 25657571
Cancer Inform. 2015 Jan 26;13:67-75. doi: 10.4137/CIN.S16351. eCollection 2014.

Modeling signal transduction in cancer cells has implications for targeting new therapies and inferring the mechanisms that improve or threaten a patient's treatment response. For transcriptome-wide studies, it has been proposed that simple correlation between a ligand and receptor...

Cite
Ruggeri C, Eng KH. Inferring active and prognostic ligand-receptor pairs with interactions in survival regression models. Cancer Inform. 2015;13:67-75doi: 10.4137/CIN.S16351.
Ruggeri, C., & Eng, K. H. (2014). Inferring active and prognostic ligand-receptor pairs with interactions in survival regression models. Cancer informatics, 1367-75. https://doi.org/10.4137/CIN.S16351
Ruggeri, Christina, and Eng, Kevin H. "Inferring active and prognostic ligand-receptor pairs with interactions in survival regression models." Cancer informatics vol. 13 (2014): 67-75. doi: https://doi.org/10.4137/CIN.S16351
Ruggeri C, Eng KH. Inferring active and prognostic ligand-receptor pairs with interactions in survival regression models. Cancer Inform. 2015 Jan 26;13:67-75. doi: 10.4137/CIN.S16351. eCollection 2014. PMID: 25657571; PMCID: PMC4310509.
Copy Download .nbib Format: NLM
Tracking the Fate and Origin of Clinically Relevant Adoptively Transferred CD8.

Science immunology

Chapuis AG, Desmarais C, Emerson R, Schmitt TM, Shibuya K, Lai I, Wagener F, Chou J, Roberts IM, Coffey DG, Warren E, Robbins H, Greenberg PD, Yee C.
PMID: 28367538
Sci Immunol. 2017 Feb;2(8). doi: 10.1126/sciimmunol.aal2568. Epub 2017 Feb 24.

Adoptively transferred tumor-specific cells can mediate tumor regression in cancers refractory to conventional therapy. Autologous polyclonal tumor-specific cytotoxic T cells (CTL) generated from peripheral blood and infused into patients with metastatic melanoma show enhanced persistence, compared to equivalent numbers...

Cite
Chapuis AG, Desmarais C, Emerson R, et al. Tracking the Fate and Origin of Clinically Relevant Adoptively Transferred CD8. Sci Immunol. 2017;2(8)doi: 10.1126/sciimmunol.aal2568.
Chapuis, A. G., Desmarais, C., Emerson, R., Schmitt, T. M., Shibuya, K., Lai, I., Wagener, F., Chou, J., Roberts, I. M., Coffey, D. G., Warren, E., Robbins, H., Greenberg, P. D., & Yee, C. (2017). Tracking the Fate and Origin of Clinically Relevant Adoptively Transferred CD8. Science immunology, 2(8), . https://doi.org/10.1126/sciimmunol.aal2568
Chapuis, Aude G, et al. "Tracking the Fate and Origin of Clinically Relevant Adoptively Transferred CD8." Science immunology vol. 2,8 (2017). doi: https://doi.org/10.1126/sciimmunol.aal2568
Chapuis AG, Desmarais C, Emerson R, Schmitt TM, Shibuya K, Lai I, Wagener F, Chou J, Roberts IM, Coffey DG, Warren E, Robbins H, Greenberg PD, Yee C. Tracking the Fate and Origin of Clinically Relevant Adoptively Transferred CD8. Sci Immunol. 2017 Feb;2(8). doi: 10.1126/sciimmunol.aal2568. Epub 2017 Feb 24. PMID: 28367538; PMCID: PMC5371351.
Copy Download .nbib Format: NLM
Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells.

Journal for immunotherapy of cancer

Pollack SM, Jones RL, Farrar EA, Lai IP, Lee SM, Cao J, Pillarisetty VG, Hoch BL, Gullett A, Bleakley M, Conrad EU, Eary JF, Shibuya KC, Warren EH, Carstens JN, Heimfeld S, Riddell SR, Yee C.
PMID: 25317334
J Immunother Cancer. 2014 Oct 14;2(1):36. doi: 10.1186/s40425-014-0036-y. eCollection 2014.

BACKGROUND: Adoptive T cell therapy represents an attractive modality for the treatment of patients with cancer. Peripheral blood mononuclear cells have been used as a source of antigen specific T cells but the very low frequency of T cells...

Cite
Pollack SM, Jones RL, Farrar EA, et al. Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells. J Immunother Cancer. 2014;2(1):36doi: 10.1186/s40425-014-0036-y.
Pollack, S. M., Jones, R. L., Farrar, E. A., Lai, I. P., Lee, S. M., Cao, J., Pillarisetty, V. G., Hoch, B. L., Gullett, A., Bleakley, M., Conrad, E. U., Eary, J. F., Shibuya, K. C., Warren, E. H., Carstens, J. N., Heimfeld, S., Riddell, S. R., & Yee, C. (2014). Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells. Journal for immunotherapy of cancer, 2(1), 36. https://doi.org/10.1186/s40425-014-0036-y
Pollack, Seth M, et al. "Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells." Journal for immunotherapy of cancer vol. 2,1 (2014): 36. doi: https://doi.org/10.1186/s40425-014-0036-y
Pollack SM, Jones RL, Farrar EA, Lai IP, Lee SM, Cao J, Pillarisetty VG, Hoch BL, Gullett A, Bleakley M, Conrad EU, Eary JF, Shibuya KC, Warren EH, Carstens JN, Heimfeld S, Riddell SR, Yee C. Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells. J Immunother Cancer. 2014 Oct 14;2(1):36. doi: 10.1186/s40425-014-0036-y. eCollection 2014. PMID: 25317334; PMCID: PMC4196009.
Copy Download .nbib Format: NLM
Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer.

Oncoimmunology

Huang RY, Francois A, McGray AR, Miliotto A, Odunsi K.
PMID: 28197366
Oncoimmunology. 2016 Oct 28;6(1):e1249561. doi: 10.1080/2162402X.2016.1249561. eCollection 2017.

Tumor-associated or -infiltrating lymphocytes (TALs or TILs) co-express multiple immune inhibitory receptors that contribute to immune suppression in the ovarian tumor microenvironment (TME). Dual blockade of PD-1 along with LAG-3 or CTLA-4 has been shown to synergistically enhance T-cell...

Cite
Huang RY, Francois A, McGray AR, et al. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology. 2016;6(1):e1249561doi: 10.1080/2162402X.2016.1249561.
Huang, R. Y., Francois, A., McGray, A. R., Miliotto, A., & Odunsi, K. (2017). Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology, 6(1), e1249561. https://doi.org/10.1080/2162402X.2016.1249561
Huang, Ruea-Yea, et al. "Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer." Oncoimmunology vol. 6,1 (2017): e1249561. doi: https://doi.org/10.1080/2162402X.2016.1249561
Huang RY, Francois A, McGray AR, Miliotto A, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology. 2016 Oct 28;6(1):e1249561. doi: 10.1080/2162402X.2016.1249561. eCollection 2017. PMID: 28197366; PMCID: PMC5283642.
Copy Download .nbib Format: NLM
CXCR6 by increasing retention of memory CD8.

Journal for immunotherapy of cancer

Muthuswamy R, McGray AR, Battaglia S, He W, Miliotto A, Eppolito C, Matsuzaki J, Takemasa T, Koya R, Chodon T, Lichty BD, Shrikant P, Odunsi K.
PMID: 34607898
J Immunother Cancer. 2021 Oct;9(10). doi: 10.1136/jitc-2021-003329.

PURPOSE: Resident memory CD8 T cells, owing to their ability to reside and persist in peripheral tissues, impart adaptive sentinel activity and amplify local immune response, and have beneficial implications for tumor surveillance and control. The current study aimed...

Cite
Muthuswamy R, McGray AR, Battaglia S, et al. CXCR6 by increasing retention of memory CD8. J Immunother Cancer. 2021;9(10)doi: 10.1136/jitc-2021-003329.
Muthuswamy, R., McGray, A. R., Battaglia, S., He, W., Miliotto, A., Eppolito, C., Matsuzaki, J., Takemasa, T., Koya, R., Chodon, T., Lichty, B. D., Shrikant, P., & Odunsi, K. (2021). CXCR6 by increasing retention of memory CD8. Journal for immunotherapy of cancer, 9(10), . https://doi.org/10.1136/jitc-2021-003329
Muthuswamy, Ravikumar, et al. "CXCR6 by increasing retention of memory CD8." Journal for immunotherapy of cancer vol. 9,10 (2021). doi: https://doi.org/10.1136/jitc-2021-003329
Muthuswamy R, McGray AR, Battaglia S, He W, Miliotto A, Eppolito C, Matsuzaki J, Takemasa T, Koya R, Chodon T, Lichty BD, Shrikant P, Odunsi K. CXCR6 by increasing retention of memory CD8. J Immunother Cancer. 2021 Oct;9(10). doi: 10.1136/jitc-2021-003329. PMID: 34607898; PMCID: PMC8491420.
Copy Download .nbib Format: NLM
A Novel Neoplastic Fusion Transcript, .

Clinical cancer research : an official journal of the American Association for Cancer Research

Liu CC, Veeraraghavan J, Tan Y, Kim JA, Wang X, Loo SK, Lee S, Hu Y, Wang XS.
PMID: 33172895
Clin Cancer Res. 2021 Feb 01;27(3):785-798. doi: 10.1158/1078-0432.CCR-20-2769. Epub 2020 Nov 10.

PURPOSE: Luminal B breast tumors are more aggressive estrogen receptor-positive (EREXPERIMENTAL DESIGN: We performed large-scale RNA sequencing analysis to identify chimerical transcripts preferentially expressed in luminal B breast cancer. The lead candidate was validated by reverse transcription PCR in...

Cite
Liu CC, Veeraraghavan J, Tan Y, et al. A Novel Neoplastic Fusion Transcript, . Clin Cancer Res. 2020;27(3):785-798doi: 10.1158/1078-0432.CCR-20-2769.
Liu, C. C., Veeraraghavan, J., Tan, Y., Kim, J. A., Wang, X., Loo, S. K., Lee, S., Hu, Y., & Wang, X. S. (2021). A Novel Neoplastic Fusion Transcript, . Clinical cancer research : an official journal of the American Association for Cancer Research, 27(3), 785-798. https://doi.org/10.1158/1078-0432.CCR-20-2769
Liu, Chia-Chia, et al. "A Novel Neoplastic Fusion Transcript, ." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,3 (2021): 785-798. doi: https://doi.org/10.1158/1078-0432.CCR-20-2769
Liu CC, Veeraraghavan J, Tan Y, Kim JA, Wang X, Loo SK, Lee S, Hu Y, Wang XS. A Novel Neoplastic Fusion Transcript, . Clin Cancer Res. 2021 Feb 01;27(3):785-798. doi: 10.1158/1078-0432.CCR-20-2769. Epub 2020 Nov 10. PMID: 33172895; PMCID: PMC7934498.
Copy Download .nbib Format: NLM
Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of Progestins.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Phung MT, Lee AW, Wu AH, Berchuck A, Cho KR, Cramer DW, Doherty JA, Goodman MT, Hanley GE, Harris HR, McLean K, Modugno F, Moysich KB, Mukherjee B, Schildkraut JM, Terry KL, Titus LJ, Jordan SJ, Webb PM, Pike MC, Pearce CL.
PMID: 33619020
Cancer Epidemiol Biomarkers Prev. 2021 May;30(5):927-935. doi: 10.1158/1055-9965.EPI-20-1355. Epub 2021 Feb 22.

BACKGROUND: Combined oral contraceptive use is associated with a decreased risk of invasive epithelial ovarian cancer (ovarian cancer). There is suggestive evidence of an inverse association between progestin-only contraceptive use and ovarian cancer risk, but previous studies have been...

Cite
Phung MT, Lee AW, Wu AH, et al. Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of Progestins. Cancer Epidemiol Biomarkers Prev. 2021;30(5):927-935doi: 10.1158/1055-9965.EPI-20-1355.
Phung, M. T., Lee, A. W., Wu, A. H., Berchuck, A., Cho, K. R., Cramer, D. W., Doherty, J. A., Goodman, M. T., Hanley, G. E., Harris, H. R., McLean, K., Modugno, F., Moysich, K. B., Mukherjee, B., Schildkraut, J. M., Terry, K. L., Titus, L. J., Jordan, S. J., Webb, P. M., Pike, M. C., Pearce, C. L. (2021). Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of Progestins. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 30(5), 927-935. https://doi.org/10.1158/1055-9965.EPI-20-1355
Phung, Minh Tung, et al. "Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of Progestins." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 30,5 (2021): 927-935. doi: https://doi.org/10.1158/1055-9965.EPI-20-1355
Phung MT, Lee AW, Wu AH, Berchuck A, Cho KR, Cramer DW, Doherty JA, Goodman MT, Hanley GE, Harris HR, McLean K, Modugno F, Moysich KB, Mukherjee B, Schildkraut JM, Terry KL, Titus LJ, Jordan SJ, Webb PM, Pike MC, Pearce CL. Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of Progestins. Cancer Epidemiol Biomarkers Prev. 2021 May;30(5):927-935. doi: 10.1158/1055-9965.EPI-20-1355. Epub 2021 Feb 22. PMID: 33619020.
Copy Download .nbib Format: NLM
Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer.

Oncotarget

Tsuji T, Eng KH, Matsuzaki J, Battaglia S, Szender JB, Miliotto A, Gnjatic S, Bshara W, Morrison CD, Lele S, Emerson RO, Wang J, Liu S, Robins H, Lugade AA, Odunsi K.
PMID: 32676168
Oncotarget. 2020 Jul 07;11(27):2669-2683. doi: 10.18632/oncotarget.27666. eCollection 2020 Jul 07.

CD8

Cite
Tsuji T, Eng KH, Matsuzaki J, et al. Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer. Oncotarget. 2020;11(27):2669-2683doi: 10.18632/oncotarget.27666.
Tsuji, T., Eng, K. H., Matsuzaki, J., Battaglia, S., Szender, J. B., Miliotto, A., Gnjatic, S., Bshara, W., Morrison, C. D., Lele, S., Emerson, R. O., Wang, J., Liu, S., Robins, H., Lugade, A. A., & Odunsi, K. (2020). Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer. Oncotarget, 11(27), 2669-2683. https://doi.org/10.18632/oncotarget.27666
Tsuji, Takemasa, et al. "Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer." Oncotarget vol. 11,27 (2020): 2669-2683. doi: https://doi.org/10.18632/oncotarget.27666
Tsuji T, Eng KH, Matsuzaki J, Battaglia S, Szender JB, Miliotto A, Gnjatic S, Bshara W, Morrison CD, Lele S, Emerson RO, Wang J, Liu S, Robins H, Lugade AA, Odunsi K. Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer. Oncotarget. 2020 Jul 07;11(27):2669-2683. doi: 10.18632/oncotarget.27666. eCollection 2020 Jul 07. PMID: 32676168; PMCID: PMC7343634.
Copy Download .nbib Format: NLM
Reprogramming antitumor immunity against chemoresistant ovarian cancer by a CXCR4 antagonist-armed viral oncotherapy.

Molecular therapy oncolytics

Komorowski MP, McGray AR, Kolakowska A, Eng K, Gil M, Opyrchal M, Litwinska B, Nemeth MJ, Odunsi KO, Kozbor D.
PMID: 28035333
Mol Ther Oncolytics. 2016 Dec 14;3:16034. doi: 10.1038/mto.2016.34. eCollection 2016.

Ovarian cancer remains the most lethal gynecologic malignancy owing to late detection, intrinsic and acquired chemoresistance, and remarkable heterogeneity. Here, we explored approaches to inhibit metastatic growth of murine and human ovarian tumor variants resistant to paclitaxel and carboplatin...

Cite
Komorowski MP, McGray AR, Kolakowska A, et al. Reprogramming antitumor immunity against chemoresistant ovarian cancer by a CXCR4 antagonist-armed viral oncotherapy. Mol Ther Oncolytics. 2016;3:16034doi: 10.1038/mto.2016.34.
Komorowski, M. P., McGray, A. R., Kolakowska, A., Eng, K., Gil, M., Opyrchal, M., Litwinska, B., Nemeth, M. J., Odunsi, K. O., & Kozbor, D. (2016). Reprogramming antitumor immunity against chemoresistant ovarian cancer by a CXCR4 antagonist-armed viral oncotherapy. Molecular therapy oncolytics, 316034. https://doi.org/10.1038/mto.2016.34
Komorowski, Marcin P, et al. "Reprogramming antitumor immunity against chemoresistant ovarian cancer by a CXCR4 antagonist-armed viral oncotherapy." Molecular therapy oncolytics vol. 3 (2016): 16034. doi: https://doi.org/10.1038/mto.2016.34
Komorowski MP, McGray AR, Kolakowska A, Eng K, Gil M, Opyrchal M, Litwinska B, Nemeth MJ, Odunsi KO, Kozbor D. Reprogramming antitumor immunity against chemoresistant ovarian cancer by a CXCR4 antagonist-armed viral oncotherapy. Mol Ther Oncolytics. 2016 Dec 14;3:16034. doi: 10.1038/mto.2016.34. eCollection 2016. PMID: 28035333; PMCID: PMC5155641.
Copy Download .nbib Format: NLM
Therapeutic cancer vaccines and combination immunotherapies involving vaccination.

ImmunoTargets and therapy

Nguyen T, Urban J, Kalinski P.
PMID: 27471705
Immunotargets Ther. 2014 Oct 06;3:135-50. doi: 10.2147/ITT.S40264. eCollection 2014.

Recent US Food and Drug Administration approvals of Provenge(®) (sipuleucel-T) as the first cell-based cancer therapeutic factor and ipilimumab (Yervoy(®)/anticytotoxic T-lymphocyte antigen-4) as the first "checkpoint blocker" highlight recent advances in cancer immunotherapy. Positive results of the clinical trials...

Cite
Nguyen T, Urban J, Kalinski P. Therapeutic cancer vaccines and combination immunotherapies involving vaccination. Immunotargets Ther. 2014;3:135-50doi: 10.2147/ITT.S40264.
Nguyen, T., Urban, J., & Kalinski, P. (2014). Therapeutic cancer vaccines and combination immunotherapies involving vaccination. ImmunoTargets and therapy, 3135-50. https://doi.org/10.2147/ITT.S40264
Nguyen, Trang, et al. "Therapeutic cancer vaccines and combination immunotherapies involving vaccination." ImmunoTargets and therapy vol. 3 (2014): 135-50. doi: https://doi.org/10.2147/ITT.S40264
Nguyen T, Urban J, Kalinski P. Therapeutic cancer vaccines and combination immunotherapies involving vaccination. Immunotargets Ther. 2014 Oct 06;3:135-50. doi: 10.2147/ITT.S40264. eCollection 2014. PMID: 27471705; PMCID: PMC4918241.
Copy Download .nbib Format: NLM
Identification of a Locus Near .

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Quinn MCJ, McCue K, Shi W, Johnatty SE, Beesley J, Civitarese A, O'Mara TA, Glubb DM, Tyrer JP, Armasu SM, Ong JS, Gharahkhani P, Lu Y, Gao B, Patch AM, Fasching PA, Beckmann MW, Lambrechts D, Vergote I, Velez Edwards DR, Beeghly-Fadiel A, Benitez J, Garcia MJ, Goodman MT, Dörk T, Dürst M, Modugno F, Moysich K, du Bois A, Pfisterer J, Bauman K, Karlan BY, Lester J, Cunningham JM, Larson MC, McCauley BM, Kjaer SK, Jensen A, Hogdall CK, Hogdall E, Schildkraut JM, Riggan MJ, Berchuck A, Cramer DW, Terry KL, Bjorge L, Webb PM, Friedlander M, Pejovic T, Moffitt M, Glasspool R, May T, Ene GEV, Huntsman DG, Woo M, Carney ME, Hinsley S, Heitz F, Fereday S, Kennedy CJ, Edwards SL, Winham SJ, deFazio A, Pharoah PDP, Goode EL, MacGregor S, Chenevix-Trench G.
PMID: 34162658
Cancer Epidemiol Biomarkers Prev. 2021 Sep;30(9):1669-1680. doi: 10.1158/1055-9965.EPI-20-1817. Epub 2021 Jun 23.

BACKGROUND: Many loci have been found to be associated with risk of epithelial ovarian cancer (EOC). However, although there is considerable variation in progression-free survival (PFS), no loci have been found to be associated with outcome at genome-wide levels...

Cite
Quinn MCJ, McCue K, Shi W, et al. Identification of a Locus Near . Cancer Epidemiol Biomarkers Prev. 2021;30(9):1669-1680doi: 10.1158/1055-9965.EPI-20-1817.
Quinn, M. C. J., McCue, K., Shi, W., Johnatty, S. E., Beesley, J., Civitarese, A., O'Mara, T. A., Glubb, D. M., Tyrer, J. P., Armasu, S. M., Ong, J. S., Gharahkhani, P., Lu, Y., Gao, B., Patch, A. M., Fasching, P. A., Beckmann, M. W., Lambrechts, D., Vergote, I., Velez Edwards, D. R., Beeghly-Fadiel, A., Benitez, J., Garcia, M. J., Goodman, M. T., Dörk, T., Dürst, M., Modugno, F., Moysich, K., du Bois, A., Pfisterer, J., Bauman, K., Karlan, B. Y., Lester, J., Cunningham, J. M., Larson, M. C., McCauley, B. M., Kjaer, S. K., Jensen, A., Hogdall, C. K., Hogdall, E., Schildkraut, J. M., Riggan, M. J., Berchuck, A., Cramer, D. W., Terry, K. L., Bjorge, L., Webb, P. M., Friedlander, M., Pejovic, T., Moffitt, M., Glasspool, R., May, T., Ene, G. E. V., Huntsman, D. G., Woo, M., Carney, M. E., Hinsley, S., Heitz, F., Fereday, S., Kennedy, C. J., Edwards, S. L., Winham, S. J., deFazio, A., Pharoah, P. D. P., Goode, E. L., MacGregor, S., Chenevix-Trench, G. (2021). Identification of a Locus Near . Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 30(9), 1669-1680. https://doi.org/10.1158/1055-9965.EPI-20-1817
Quinn, Michael C J, et al. "Identification of a Locus Near ." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 30,9 (2021): 1669-1680. doi: https://doi.org/10.1158/1055-9965.EPI-20-1817
Quinn MCJ, McCue K, Shi W, Johnatty SE, Beesley J, Civitarese A, O'Mara TA, Glubb DM, Tyrer JP, Armasu SM, Ong JS, Gharahkhani P, Lu Y, Gao B, Patch AM, Fasching PA, Beckmann MW, Lambrechts D, Vergote I, Velez Edwards DR, Beeghly-Fadiel A, Benitez J, Garcia MJ, Goodman MT, Dörk T, Dürst M, Modugno F, Moysich K, du Bois A, Pfisterer J, Bauman K, Karlan BY, Lester J, Cunningham JM, Larson MC, McCauley BM, Kjaer SK, Jensen A, Hogdall CK, Hogdall E, Schildkraut JM, Riggan MJ, Berchuck A, Cramer DW, Terry KL, Bjorge L, Webb PM, Friedlander M, Pejovic T, Moffitt M, Glasspool R, May T, Ene GEV, Huntsman DG, Woo M, Carney ME, Hinsley S, Heitz F, Fereday S, Kennedy CJ, Edwards SL, Winham SJ, deFazio A, Pharoah PDP, Goode EL, MacGregor S, Chenevix-Trench G. Identification of a Locus Near . Cancer Epidemiol Biomarkers Prev. 2021 Sep;30(9):1669-1680. doi: 10.1158/1055-9965.EPI-20-1817. Epub 2021 Jun 23. PMID: 34162658; PMCID: PMC8419101.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 21 entries